Key Points
Different metabolic pathways are involved in intracellular metabolic reprogramming depending on the genetic characteristics of AML cells.

Leukemic progenitors activate different programs of the metabolism, depending on their levels of differentiation blockade.

(Article continues at link.)

Dear members of the PNH community, 

Despite only one new FDA approval in 2020 for treatment of patients with

Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with

Stem cell transplants are not frequently offered to older patients with high-risk

The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta. DocWire News interviewed Tony Lin, Pharm.D., a Senior Scientific Director with AbbVie US medical affairs, to discuss this more in-depth. Dr. Lin is a

TP53-mutant

Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with

Abstract
Objective/Background